<!DOCTYPE html><html><head><title> Pacifica Code Section 58-17b-S805 </title><link rel="stylesheet" href="/assets/style.css"/></head><body>
<b><i>
                      Effective 5/14/2019</i></b>
<br>
<b>58-17b-805.&nbsp;
          </b><b>Dispensing medical practitioner -- Cancer drug treatment regimen.</b>
<br>
<a id="58-17b-805(1)" name="58-17b-805(1)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(1)</td><td style="width:99%">
For purposes of this section:
<a id="58-17b-805(1)(a)" name="58-17b-805(1)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
"Cancer drug treatment regimen" means a prescription drug used to treat cancer, manage its symptoms, or provide continuity of care for a cancer patient.</td>
</tr>
</tbody></table>
<a id="58-17b-805(1)(b)" name="58-17b-805(1)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
"Cancer drug treatment regimen" includes:<a id="58-17b-805(1)(b)(i)" name="58-17b-805(1)(b)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
a chemotherapy drug administered intravenously, orally, rectally, or by dermal methods; and</td>
</tr>
</tbody></table>
<a id="58-17b-805(1)(b)(ii)" name="58-17b-805(1)(b)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
a drug used to support cancer treatment, including a drug used to treat, alleviate, or minimize physical and psychological symptoms or pain, to improve patient tolerance of cancer treatments, or to prepare a patient for a subsequent course of therapy.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="58-17b-805(1)(c)" name="58-17b-805(1)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
"Cancer drug treatment regimen" does not mean a drug listed under federal law as a Schedule I, II, or III drug.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="58-17b-805(2)" name="58-17b-805(2)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(2)</td><td style="width:99%">
An individual may be licensed as a dispensing medical practitioner with a scope of practice that permits the dispensing medical practitioner to prescribe and dispense a cancer drug treatment regimen if the individual:
<a id="58-17b-805(2)(a)" name="58-17b-805(2)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
is licensed as described in Subsections <a href="../../Title58/Chapter17B/58-17b-S102.html?v=C58-17b-S102_2019051420190514#58-17b-102(23)(a)(i)">58-17b-102(23)(a)(i)</a> and <a href="../../Title58/Chapter17B/58-17b-S102.html?v=C58-17b-S102_2019051420190514#58-17b-102(23)(a)(ii)">(ii)</a>; and</td>
</tr>
</tbody></table>
<a id="58-17b-805(2)(b)" name="58-17b-805(2)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
is certified or eligible to be certified by:<a id="58-17b-805(2)(b)(i)" name="58-17b-805(2)(b)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
the American Board of Internal Medicine in medical oncology; or</td>
</tr>
</tbody></table>
<a id="58-17b-805(2)(b)(ii)" name="58-17b-805(2)(b)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
the American Board of Urology.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="58-17b-805(3)" name="58-17b-805(3)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(3)</td><td style="width:99%">
A dispensing medical practitioner authorized to prescribe and dispense a cancer drug treatment regimen under this section may prescribe and dispense a cancer drug treatment regimen:
<a id="58-17b-805(3)(a)" name="58-17b-805(3)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
to the practitioner's patient who is currently undergoing chemotherapy in an outpatient clinic setting; and</td>
</tr>
</tbody></table>
<a id="58-17b-805(3)(b)" name="58-17b-805(3)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
if the practitioner determines that providing the cancer drug treatment regimen to the patient in the outpatient clinic setting is in the best interest of the patient or provides better access to care for the patient.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<br>
<br>Amended by Chapter <a href="http://le.utah.gov/UtahCode/ChapterLookup.jsp?chap=343&amp;sess=2019GS">343</a>, 2019 General Session<br>
</body></html>